The nation has its answer—and gets a reprieve from the constant swarm of political ads—but now what? NCPA has put together this election analysis on what the election might mean for independent pharmacies and the health care system overall. You may have seen the Executive Update NCPA CEO B. Douglas Hoey delivered today. If you missed it, here’s the upshot: we just don’t know. Appointments to Health and Human Services and Centers for Medicare/Medicaid will be crucial. Trump has said he’ll repeal the Affordable Care Act. Stock prices have climbed for drug manufacturers and PBMs (indicating the market’s belief that the new administration will treat their interests favorably). But, says Hoey, small business owners made up a solid contingent of the president-elect and Congress’s base and may well gain more attention from a Trump administration that they did under Bush or Obama. Stay tuned.
Here are few stories that might be of interest:
· Right time, wrong approach, says California electorate. A controversial ballot measure on drug pricing was voted down.
· Need a break? Read about the benefits of controlled breathing.
· There’s still a lot we don’t know. Here’s an update on Zika.
· Post-Diplomat-crash, here’s another look at DIR fees.
· Bloomberg’s science and health reporter, Robert Langreth, frequent talks drug pricing. Here’s the latest on drug overpayment.
[Editor’s note:] Our inboxes are stuffed with newsletters and our coffee tables stacked with magazines and industry digests. I’m sure yours are, too. So we’ve decided to run a weekly sampling of interesting stories, issues coverage, and business ideas we come across this week. We hope you’ll share some of your favorites, too. Drop us a line at email@example.com.